Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

NCT07304232 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

134

Enrollment

OTHER

Sponsor class

Conditions

Allogeneic Hematopoietic Cell Transplantation (HCT)
AML (Acute Myeloid Leukemia)

Interventions

DRUG: Chidamide

Sponsor

Institute of Hematology & Blood Diseases Hospital, China